Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Companion Diagnostics Market be in 2030 compared with 2026?

The companion diagnostics market has experienced rapid expansion over recent years. It is forecast to grow from $8.69 billion in 2025 to $10.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 21.3%. This historic expansion can be attributed to the proliferation of targeted cancer therapies, the increasing scope of oncology clinical trials, enhanced collaboration between pharmaceutical and diagnostics companies, rising cancer incidence rates, and regulatory approvals for companion tests.

The companion diagnostics market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $22.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 21.1%. The anticipated growth during this period stems from factors such as a heightened need for tailored treatment options, increased financial commitments in precision medicine, the broadening of immuno-oncology research and development, a surge in the embrace of AI-powered diagnostic analysis, and greater regulatory attention on the collaborative development of diagnostics and drugs. Key developments expected throughout the forecast period involve a greater uptake of precision oncology diagnostics, the escalating incorporation of companion diagnostics into drug development processes, the expanding utilization of NGS-based diagnostic platforms, the growth of therapies guided by biomarkers, and a reinforced emphasis on individualized medicine.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

What Drivers Are Guiding Growth Patterns In The Companion Diagnostics Market?

A rising volume of targeted therapies is anticipated to stimulate expansion within the companion diagnostics market. Targeted therapy refers to a pharmacological approach designed to inhibit the proliferation and dissemination of cancer by focusing on specific attributes of cancer cells. These medications, while circulating systemically, exert a more precise effect compared to chemotherapy, often resulting in fewer side effects. Companion diagnostic testing, utilizing biological markers for targeted cancer therapy, is progressively becoming a crucial component of personalized cancer care. For example, in February 2024, data from the Personalized Medicine Coalition, a US-based hospital and health care organization, indicated that in 2023, the FDA sanctioned 16 novel personalized treatments for patients with rare diseases, an increase from 6 in 2022. Consequently, the expansion of targeted therapies fuels the growth in the companion diagnostics market.

Which Segments Are Driving Activity In The Companion Diagnostics Market?

The companion diagnostics market covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

What Trends Are Reshaping The Dynamics Of The Companion Diagnostics Market?

Key companies operating in the companion diagnostics market are establishing collaborations to formulate advanced treatment strategies aimed at enhancing personalized medicine, improving patient outcomes, and optimizing the effectiveness of targeted therapies. Such partnerships are anticipated to expedite the development and commercialization of companion diagnostics (CDx) for both hematology and oncology treatments. As an illustration, in January 2024, Agilent Technologies, Inc., a US-based company supplying instruments, software, services, and consumables for laboratories, announced an agreement with Incyte, a US-based pharmaceutical company. This arrangement will combine Agilent’s proficiency and extensive experience in the creation of companion diagnostics (CDx) to facilitate the development and market launch of Incyte’s hematology and oncology product lineup. This collaboration enables Agilent to broaden its CDx portfolio with new biomarkers, while Incyte benefits from Agilent’s expertise in assay development, regulatory approvals, and commercialization to back clinical trials and CDx registration in the U.S. and Europe.

Which Key Players Are Driving Competition In The Companion Diagnostics Market?

Major companies operating in the companion diagnostics market are F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sysmex Corporation, Ventana Medical Systems

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Which Region Is Projected To Lead The Companion Diagnostics Market During The Forecast Period?

North America was the largest region in the companion diagnostics market in 2025. The regions covered in the companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Companion Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

Browse Through More Reports Similar to the Global Companion Diagnostics Market 2026, By The Business Research Company

Contact Lenses Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/contact-lenses-global-market-report

Bionic Contact Lenses Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bionic-contact-lenses-global-market-report

Smart Contact Lenses Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-contact-lenses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company